5. REFERENCES

- Adriana, G., Pluteanub, F., Flontab, M.L., Badilac, E., Dorobantuc, M., Popov, D. (2005). The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. European Journal of Pharmacology, 508, 159–166.

- Alderman, M.H. (2008). New onset diabetes during antihypertensive therapy. Am J Hypertens, 21(5), 493–499.

- ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic, the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 288, 2981–2997.

- Anna, K., Sun, T.H., Patel, K.P., Mayhan, W.G. (2003). Enalapril Prevents Impaired Nitric Oxide Synthase–Dependent Dilatation of Cerebral Arterioles in Diabetic Rats. Stroke, 34, 2698-2703.

- Bangalore, S., Parkar, S., Grossman, E., Messerli, F. (2007). A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol, 100(8), 1254–1262.

- Calo, L., Davis, P.A., Cantaro, S., Bonfante, L., Castrignano, R., Carraro, G., D'Angelo, A. (1998). Effect of doxazosin in mild to moderate hypertensive patients with insulin dependent diabetes mellitus. Acta Diabetol 35, 96–100.

- Carl J. Pepine, Cooper, R.M., DeHoff. (2004). Cardiovascular Therapies and Risk for Development of Diabetes. JACC 44, 3, 509-512.

- Chen, J., Gu, H. (2002). Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chin Med J (Engl), 115(7), 972-978.

- Derosa, G., Cicero, A.F. (2004). Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension, a 12-month, randomized, double-blind study. Clin Ther, 26(8), 1228-1236.

- Ebbehøj, E., Arildsen, H., Hansen, W., Mogensen, C. E., Mølgaard, H., Poulsen, P. L. (2004). Effects of metoprolol on QT interval and QT dispersion in Type 1 diabetic patients with abnormal albuminuria. Diabetologia, 47, 1009–1015.

- Elena, M.V., Cavanagh, D., Inserra, F., Toblli, J., Stella, I., Fraga, C.G., Ferder, L. (2001). Enalapril Attenuates Oxidative Stress in Diabetic Rats. Hypertension, 38,1130- 1136

- Emmanuelle, V., Ducharme, A., Martial, G., Lessard, B.M., White, M., Tardif, J.C. (2003). Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure Insight From the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation, 107,1291-1296

- Erdamar, H., Sen, N. (2009). The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis, 20(3), 238-234.

- George, L., Bakris, Fonseca, V., Katholi, R.E., McGill, J.B., Messerli, F.H., Robert, A., Raskin, P.P., GEMINI Investigators. (2004). Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension A Randomized Controlled Trial. JAMA, 292, 2227-2236

- Hansson, L., Hedner, T., Lund-Johansen, P. (2000). Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension, the nordic diltiazem. (NORDIL) study. Lancet, 356, 359–365.

- Harris, M.I., (2000). Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care, 23, 754–758.

- Huang, H.E., Jiang, S., Xiao-Hong, P., Hui-Ping, W., Ling, Q. (2006). Carvedilol protected diabetic rat hearts via reducing oxidative stress. J Zhejiang Univ SCIENCE B, 7(9), 725-731.

- International Diabetes Federation (IDF), Facts and figures, did you know? www.idf.org. Assessed on May 22, 2007.

- Istvan, E., Gasiorb, Z., Wita, K. (2005). Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure, results of the ENECA study. The European Journal of Heart Failure, 7 631– 639.

- King, H., Aubert, R.E., Herman, W.H., (1998). Global burden of diabetes, 1995–2025, prevalence, numerical estimates, and projections. Diab. Care, 21, 1414–1431.

- Ko, G.T., Chan, H.C. (2001). Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension, a randomized 1-year clinical trial. Int J Clin Pharmacol Ther, 39(8), 331-335.

- Koshiyama, H., Tanaka, S. (1999). Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. J Cardiovasc Pharmacol, 33(6), 894-896.

- Kuti, E.L., Baker, W.L. (2007). The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker. Curr Med Res Opin, 23(6), 1239-1244.

- Mahmoudian, M., Behnaz, F. (1996). Diabetes-induced changes in the contractility of the aorta and pA2 of nifedipine in the rat. Acta Diabetol, 33(2), 114-117.

- Mancia, G., Brown, M., Castaigne, A. (2003). Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension, 41, 431–436.

- Marco P., Psaty, B.M., Alderman, M.H., Applegate, W. (2000). Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients with Type 2 Diabetes. Diabetes Care, 23,888–892

- Masahiro, T., Shou, I., Tomino, Y. (1998). Effects of the Antihypertensive Drug Efonidipine Hydrochloride on Albuminuria and Renal Histopathology in Young Spontaneously Hypertensive Rats with Diabetes. Gen. Pharmac, 30, 5, 749–752.

- Matthias, O., Daiber, A., Brandes, R.P., Hortmann, M., Wenzel, P. (2006). Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin II–Treated Rats Hypertension, 48,677-684.

- Paul, M.L., Janssen, Zeitz, O., Hasenfuss, G. (1999). Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function, protective effects of nebivolol. European Journal of Pharmacology, 366, 223–232.

- Qu, F.Z., Liu, Z.H. (2009). Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure. Zhonghua Xin Xue Guan Bing Za Zhi, 37(6), 501-504.

- Sarah, E.C., Hertzel, C., Gerstein. (2000). Enalapril Prevents Clinical Proteinuria in Diabetic Patients With Low Ejection fraction. Diabetes Care, 23, 377–380.

- Shigihara, T., Sato, A. (2000). Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res, 23(3), 219-226.

- Shougo, K., Takizawa, H., Takeda, M., Shou, I., Tomino, Y. (1999). Effects of the antihypertensive drug nifedipine on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes. General Pharmacology, 33 363–367.

- The DREAM Trial Investigators. (2006). Effect of ramipril on the incidence of diabetes. New Engl J Med, 355, 1551–1562.

- UK Prospective Diabetes Study Group. (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes, UKPDS 38. BMJ, 317, 703–712.

- Verdecchia, P., Reboldi, G., Angeli, F. (2004). Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension; 43(5), 963–969.

- WHO Consultation. (1999). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1, diagnosis and classification of diabetes mellitus. Geneva, Report No. 99.2.

- Winer, N., Folker, A. (2005). Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol, 8(2), 87-92.

- Zahid, D., Yasmin, Carmel, M., McEniery, Burton, T., Morris, J., Brown, I.B., Wilkinson. (2008). A comparison of atenolol and nebivolol in isolated systolic Hypertension. Journal of Hypertension, 26,351–356.